Background. The occurrence of second malignant neoplasms (SMNs) in successfully treated
pediatric patients with cancer has been an area of increasing concern because survival of …

PURPOSE This study was performed to determine the incidence and risk factors involved in
the development of a second malignant neoplasm (SMN) after treatment of primary …

AIM: The RMS4. 99 study was designed to explore the role of multiple sequential high-dose
chemotherapy cycles administered early in the treatment of children with metastatic …

BACKGROUND: Despite advances in therapy, nearly 30% of children with
rhabdomyosarcoma experience progressive or relapsed disease, which is often fatal …

Abstract BACKGROUND: Rhabdomyosarcoma (RMS), the most common soft‐tissue
sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have …

Currently, approximately 67% of children diagnosed with cancer can be expected to survive
more than 5 years. Among the most significant late effects of cancer therapy is the …

Purpose Intergroup Rhabdomyosarcoma Study Group (IRSG) studies III and IV showed
improved failure-free survival (FFS) rates with vincristine, dactinomycin, and …

The aim of our study was to describe late failures in children who initially survived event-free
five years from a diagnosis of rhabdomyosarcoma. Charts of children enrolled in the …

BACKGROUND The management of rhabdomyosarcoma (RMS) in patients age< 1 year is
particularly problematic and requires a tailored therapeutic approach. We report on the …

Purpose Previous studies suggest poor outcome in children with relapsed
rhabdomyosarcoma (RMS). A better understanding is needed of which patients can be …